Dry Eye DiseaseNCT01775540
Systane Ultra Versus Maxidex Versus Saline
A study testing Systane Ultra, Saline solution and Maxidex in people with Dry Eye Disease, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
Trial summary
This study was to evaluate the healing action on the eye surface of the artificial tear Systane® ULTRA as compared to two other eyedrops: Maxidex and Saline solution. Dry eye disease leads to inflammation of the eye surface and treating dry eyes with artificial tears may lead to reduction in this inflammation and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Dry Eye Disease
- What is being tested?
- Systane Ultra, Saline solution and Maxidex
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- May 2012to Oct 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A score of at least 15 on the Ocular Surface Discomfort Index (OSDI) symptom questionnaire.
- Moderate vital staining, fluorescein (for corneal evaluation, 3-15 on the NEI scale) OR lissamine (for conjunctival evaluation, score of 2-6; temporal and nasal areas, each graded 0-3).
- Willingness to use study drugs 4 times per day in both eyes.
- Willingness to discontinue use of other artificial tear products.
- Patient must provide written informed consent
- Patient must understand the scope of the study including completion of worksheet and be willing to follow instructions and return for all required study visits
- An intraocular pressure less than or equal to 22 mmHg in both eyes
Who cannot join
- Contact Lens wearers
- Pregnant and/or lactating women
- Those with moderate to severe Meibomian Gland Disease i.e. plugging of 3 or more glands and/or pasty secretion from 3 or more glands or presence of obstructed glands out of a total of 10 glands evaluated in the central portion of the lower lid.
- Uncontrolled systemic or ocular disease
- Dry eye due to seasonal allergic conjunctivitis, contact lens related conjunctivitis or other acute or seasonal diagnosis.
- Are monocular and/or legally blind
Show all 10Show fewer
- Had ocular surgery or trauma within last six months
- Participation in an ophthalmic drug or device research study within 30 days prior to entry in this study
- Current use of any eye drops other than artificial tears
- Use of Restasis within three months prior to entry in this study
Trial locations and contacts
1 site in 1 country.
United States1 site
Mount Sinai School of Medicine
New York, New York, 10029
About this study
Official title: Study to Evaluate the Ocular Surface Healing Action of the Artificial Tear Systane ULTRA Using Both Positive (Maxidex) and Negative (Saline Solution) Controls
This study was to evaluate the healing action on the eye surface of the artificial tear Systane® ULTRA as compared to two other eyedrops: Maxidex and Saline solution. Dry eye disease leads to inflammation of the eye surface and treating dry eyes with artificial tears may lead to reduction in this inflammation and improvement of symptoms and signs.
Read the detailed description
For all patients who present to the office with a history of dry eyes:
- Consent forms will be obtained from every patient. Informed consent will be discussed with the patient in detail. Every topic will be addressed separately. All risks, benefits, and alternatives will be discussed. Patient will be allowed to ask questions, and all questions will be answered. The assessment will be made after that conversation, whether or not the patient understood the consent as described above. Each subject will be allowed as much time as needed to review and sign the consent forms.
- All patients will be asked to fill out the Ocular Surface Discomfort Index (OSDI) questionnaire to ensure they meet the inclusion criteria. If patients score meets eligibility requirements a general and ocular history will be taken. (Time: 10 min)
- A pregnancy test will be given to all female subjects of child bearing age. A standard eye exam will be performed to rule out any other ocular pathology besides refractive error. This allows for confirmation that all study subjects have dry eye disease. Topical fluorescein and lissamine dye will be used to record staining on the cornea and conjunctiva of subjects as well as the tear film break-up time (TFBUT). Both of these dyes are used as standard-of-care in eye exams around the country. TFBUT will first be determined through application of sodium fluorescein onto the eye using DET strip. Following triplicate evaluation of TFBUT in each eye, ocular staining will be determined with liquid fluorescein and lissamine dyes administered in liquid form. (Time 15 min).
- Patients will be given Alcon questionnaires to fill out, inquiring about past treatments, daily symptoms and distress associated with their dry eye disease. (Time:15 minutes) This also serves as a waiting period for some of the dye to wash out.
- Using a graduated disposable 5 µl microcapillary tube (Wiretol-Micropipettes, Drummond Scientific Co., Broomall, PA, USA) up to 5 µl of tears / eye will be collected from the inferior temporal tear meniscus of each participant, without corneal anesthesia, taking care to ensure that the lid margin and corneal surface were not touched. A maximum of 5 minutes will be allowed per eye for collection of minimal 5 uL of tear. Tears will be immediately dispensed into pre-labeled Eppendorf tubes and placed on dry ice until transferred to -80oC for storage. (Time: 10 minutes)
- A technique known as Impression Cytology (IC) will be used to isolate epithelial cells from the conjunctiva. Anesthetic drops will be administered to each eye before the procedure. Blunted forceps are used to gently press a piece of filter paper against the patient's conjunctiva. The paper is gently lifted off, and sent to the Mount Sinai Laboratory for analyses. (Estimated collection time: 15 minutes). A total of 6 pieces per patient (3 pieces per eye) will be collected on each scheduled visit. For HLA-DR analysis, 2 pieces from each eye will be held at room temperature in a vial containing fixative until assay. The remaining 1 piece from each eye will be pooled together in one vial for RT-PCR assays in the following order: (1) immediately merged into a pre-labeled Eppendorf tube with 600 µL of TriZol Reagent; (2) Vortex for 30 seconds; (3) sealed with Saran Wrap; (4) transfer to -80C for storage until assay.
- Measurement of Intraocular pressure using Tonopen.
- As a part of the substudy we intend to treat patients with Systane ULTRA®, Maxidex, (both of which are FDA approved ophthalmic solutions), or the saline solution placebo. Subjects will be assigned to one of the three groups as per randomization sequence and the corresponding eye drop will be dispensed.
- The patient's response to treatment will be assessed after approximately 4 weeks (+/- 5 days) using the same diagnostic tests in order to assess the sensitivity of these diagnostic tests to detect the response to medical treatment of dry eye disease. In addition to baseline and 4 week visits, safety evaluations will be performed at a 2 week (+/- 5 days) visit. All the procedures done during the baseline visit will be repeated except pregnancy test, tear collection and impression cytology.
- Conditions
- Dry Eye Disease
- Being tested
- Systane Ultra, Saline solution, Maxidex
- Keywords
- Dry eye, Artificial tears, Ocular surface inflammation
- Medical subject headings
- Dry Eye Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Systane UltraDrug
Also called Artificial Tears
Artificial tear Eyedrop, 1 drop used QID for 4 weeks
Saline solutionDrug
Saline solution,1 drop used QID for 4 weeks
MaxidexDrug
Also called Dexamethasone 0.1% eyedrop
Eyedrop-1 drop QID for 4 weeks
| Study group | Role | What they receive |
|---|---|---|
| Systane Ultra | Experimental | Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks Receives: Drug: Systane Ultra |
| Saline solution | Placebo comparator | Saline solution Eyedrop, 1 drop used QID for 4 weeks Receives: Drug: Saline solution |
| Maxidex | Active comparator | Steroid eyedrop, 1 drop QID for 4 weeks Receives: Drug: Maxidex |
What is being measured
The primary outcome is the main question the study is designed to answer.
OSDI score
questionnaire pertaining to dry eye symptoms answered by patients
Measured: at Baseline
OSDI score
questionnaire pertaining to dry eye symptoms answered by patients
Measured: visit 2 (at 2 weeks)
OSDI score
questionnaire pertaining to dry eye symptoms answered by patients
Measured: at visit 3 (at 4 weeks)
Secondary outcomes (21)
Tear Film break up time
Time taken for the first dry spot to appear in the tear film
Measured: at Baseline
Tear Film break up time
Time taken for the first dry spot to appear in the tear film
Measured: at visit 2 (at 2 weeks)
Tear Film break up time
Time taken for the first dry spot to appear in the tear film
Measured: at visit 3 (at 4 weeks)
Corneal Staining
Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale
Measured: at Baseline
Corneal Staining
Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale
Measured: at visit 2 (at 2 weeks)
Corneal Staining
Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale
Measured: at visit 3 (at 4 weeks)
Conjunctival Staining
Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale
Measured: at Baseline
Conjunctival Staining
Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale
Measured: at visit 2 (at 2 weeks)
Conjunctival Staining
Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale
Measured: at visit 3 (at 4 weeks)
Best corrected visual acuity
BSCVA using ETDRS charts
Measured: at Baseline
Best corrected visual acuity
BSCVA using ETDRS charts
Measured: at visit 2 (at 2 weeks)
Best corrected visual acuity
BSCVA using ETDRS charts
Measured: at visit 3 (at 4 weeks)
Tear Cytokines
Tear samples collected from both eyes using microcapillary tube. Samples analysed for inflammatory cytokines using Luminex bioassays
Measured: At baseline
Tear Cytokines
Tear samples collected from both eyes using microcapillary tube. Samples analysed for inflammatory cytokines using Luminex bioassays
Measured: At visit 3 (at 4 weeks)
mRNA for HLA-DR
Cell samples collected via impression cytology and analysed for mRNA expression via flowcytometer
Measured: At baseline
mRNA for HLA-DR
Cell samples collected via impression cytology and analysed for mRNA expression via flowcytometer
Measured: At visit 3 (at 4 weeks)
HLA-DR expression
Cell samples collected via impression cytology and analysed for HLA-DR expression via flowcytometer
Measured: At baseline
HLA-DR expression
Cell samples collected via impression cytology and analysed for HLA-DR expression via flowcytometer
Measured: At visit 3 (at 4 weeks)
IDEEL questionnaire
questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients
Measured: At baseline
IDEEL questionnaire
questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients
Measured: At visit 2 (at 2 weeks)
IDEEL questionnaire
questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients
Measured: At visit 3 (at 4 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2013 (estimated)
- Study startMay 2012
- Primary completionOct 2012
- Study completionOct 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry Eye DiseaseStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Collaborators
- Alcon Research
- Responsible party
- Principal investigator, Penny Asbell, Icahn School of Medicine at Mount Sinai
- Investigators
- Penny Asbell, MD, MBA, FACS, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01775540
- Sponsor's protocol ID
- GCO 11-1230
- Status last verified
- Jan 2013
- First submitted
- 7 Dec 2012
- Last updated
- 25 Jan 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study to Evaluate the Ocular Surface Healing Action of the Artificial Tear Systane ULTRA Using Both Positive (Maxidex) and Negative (Saline Solution) Controls
- ClinicalTrials.gov ID
- NCT01775540
- Acronym / sponsor ID
- GCO 11-1230
- Conditions
- Dry Eye Disease
- Keywords
- Dry eye, Artificial tears, Ocular surface inflammation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Icahn School of Medicine at Mount SinaiUniversity, hospital or other
- Collaborators
- Alcon Research
- Study start
- May 2012
- Primary completion
- Oct 2012 (actual)
- Study completion
- Oct 2012 (actual)
- First posted
- 25 Jan 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was to evaluate the healing action on the eye surface of the artificial tear Systane® ULTRA as compared to two other eyedrops: Maxidex and Saline solution. Dry eye disease leads to inflammation of the eye surface and treating dry eyes with artificial tears may lead to reduction in this inflammation and improvement of symptoms and signs.
Detailed description
For all patients who present to the office with a history of dry eyes:
- Consent forms will be obtained from every patient. Informed consent will be discussed with the patient in detail. Every topic will be addressed separately. All risks, benefits, and alternatives will be discussed. Patient will be allowed to ask questions, and all questions will be answered. The assessment will be made after that conversation, whether or not the patient understood the consent as described above. Each subject will be allowed as much time as needed to review and sign the consent forms.
- All patients will be asked to fill out the Ocular Surface Discomfort Index (OSDI) questionnaire to ensure they meet the inclusion criteria. If patients score meets eligibility requirements a general and ocular history will be taken. (Time: 10 min)
- A pregnancy test will be given to all female subjects of child bearing age. A standard eye exam will be performed to rule out any other ocular pathology besides refractive error. This allows for confirmation that all study subjects have dry eye disease. Topical fluorescein and lissamine dye will be used to record staining on the cornea and conjunctiva of subjects as well as the tear film break-up time (TFBUT). Both of these dyes are used as standard-of-care in eye exams around the country. TFBUT will first be determined through application of sodium fluorescein onto the eye using DET strip. Following triplicate evaluation of TFBUT in each eye, ocular staining will be determined with liquid fluorescein and lissamine dyes administered in liquid form. (Time 15 min).
- Patients will be given Alcon questionnaires to fill out, inquiring about past treatments, daily symptoms and distress associated with their dry eye disease. (Time:15 minutes) This also serves as a waiting period for some of the dye to wash out.
- Using a graduated disposable 5 µl microcapillary tube (Wiretol-Micropipettes, Drummond Scientific Co., Broomall, PA, USA) up to 5 µl of tears / eye will be collected from the inferior temporal tear meniscus of each participant, without corneal anesthesia, taking care to ensure that the lid margin and corneal surface were not touched. A maximum of 5 minutes will be allowed per eye for collection of minimal 5 uL of tear. Tears will be immediately dispensed into pre-labeled Eppendorf tubes and placed on dry ice until transferred to -80oC for storage. (Time: 10 minutes)
- A technique known as Impression Cytology (IC) will be used to isolate epithelial cells from the conjunctiva. Anesthetic drops will be administered to each eye before the procedure. Blunted forceps are used to gently press a piece of filter paper against the patient's conjunctiva. The paper is gently lifted off, and sent to the Mount Sinai Laboratory for analyses. (Estimated collection time: 15 minutes). A total of 6 pieces per patient (3 pieces per eye) will be collected on each scheduled visit. For HLA-DR analysis, 2 pieces from each eye will be held at room temperature in a vial containing fixative until assay. The remaining 1 piece from each eye will be pooled together in one vial for RT-PCR assays in the following order: (1) immediately merged into a pre-labeled Eppendorf tube with 600 µL of TriZol Reagent; (2) Vortex for 30 seconds; (3) sealed with Saran Wrap; (4) transfer to -80C for storage until assay.
- Measurement of Intraocular pressure using Tonopen.
- As a part of the substudy we intend to treat patients with Systane ULTRA®, Maxidex, (both of which are FDA approved ophthalmic solutions), or the saline solution placebo. Subjects will be assigned to one of the three groups as per randomization sequence and the corresponding eye drop will be dispensed.
- The patient's response to treatment will be assessed after approximately 4 weeks (+/- 5 days) using the same diagnostic tests in order to assess the sensitivity of these diagnostic tests to detect the response to medical treatment of dry eye disease. In addition to baseline and 4 week visits, safety evaluations will be performed at a 2 week (+/- 5 days) visit. All the procedures done during the baseline visit will be repeated except pregnancy test, tear collection and impression cytology.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Systane Ultra | Experimental | Drug: Systane UltraArtificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks |
| Saline solution | Placebo comparator | Drug: Saline solutionSaline solution Eyedrop, 1 drop used QID for 4 weeks |
| Maxidex | Active comparator | Drug: MaxidexSteroid eyedrop, 1 drop QID for 4 weeks |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- A score of at least 15 on the Ocular Surface Discomfort Index (OSDI) symptom questionnaire.
- Moderate vital staining, fluorescein (for corneal evaluation, 3-15 on the NEI scale) OR lissamine (for conjunctival evaluation, score of 2-6; temporal and nasal areas, each graded 0-3).
- Willingness to use study drugs 4 times per day in both eyes.
- Willingness to discontinue use of other artificial tear products.
- Patient must provide written informed consent
Key exclusion criteria (10 listed)
- Contact Lens wearers
- Pregnant and/or lactating women
- Those with moderate to severe Meibomian Gland Disease i.e. plugging of 3 or more glands and/or pasty secretion from 3 or more glands or presence of obstructed glands out of a total of 10 glands evaluated in the central portion of the lower lid.
- Uncontrolled systemic or ocular disease
- Dry eye due to seasonal allergic conjunctivitis, contact lens related conjunctivitis or other acute or seasonal diagnosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Systane UltraAlso: Artificial TearsArtificial tear Eyedrop, 1 drop used QID for 4 weeks | Drug | Systane Ultra |
| Saline solutionSaline solution,1 drop used QID for 4 weeks | Drug | Saline solution |
| MaxidexAlso: Dexamethasone 0.1% eyedropEyedrop-1 drop QID for 4 weeks | Drug | Maxidex |
Primary outcome
OSDI score
Time frame: at Baseline
questionnaire pertaining to dry eye symptoms answered by patients
OSDI score
Time frame: visit 2 (at 2 weeks)
questionnaire pertaining to dry eye symptoms answered by patients
OSDI score
Time frame: at visit 3 (at 4 weeks)
questionnaire pertaining to dry eye symptoms answered by patients
21 secondary outcomes
Tear Film break up time
Time frame: at Baseline
Tear Film break up time
Time frame: at visit 2 (at 2 weeks)
Tear Film break up time
Time frame: at visit 3 (at 4 weeks)
Corneal Staining
Time frame: at Baseline
Corneal Staining
Time frame: at visit 2 (at 2 weeks)
Corneal Staining
Time frame: at visit 3 (at 4 weeks)
Conjunctival Staining
Time frame: at Baseline
Conjunctival Staining
Time frame: at visit 2 (at 2 weeks)
Conjunctival Staining
Time frame: at visit 3 (at 4 weeks)
Best corrected visual acuity
Time frame: at Baseline
Best corrected visual acuity
Time frame: at visit 2 (at 2 weeks)
Best corrected visual acuity
Time frame: at visit 3 (at 4 weeks)
Tear Cytokines
Time frame: At baseline
Tear Cytokines
Time frame: At visit 3 (at 4 weeks)
mRNA for HLA-DR
Time frame: At baseline
mRNA for HLA-DR
Time frame: At visit 3 (at 4 weeks)
HLA-DR expression
Time frame: At baseline
HLA-DR expression
Time frame: At visit 3 (at 4 weeks)
IDEEL questionnaire
Time frame: At baseline
IDEEL questionnaire
Time frame: At visit 2 (at 2 weeks)
IDEEL questionnaire
Time frame: At visit 3 (at 4 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2013.
Related trials for Dry Eye Disease
Not yet recruiting
Performance Evaluation of the OCUTOP Hand-held Corneal Topographer
Corneal Topography, Dry Eye Syndromes
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
Not yet recruitingPhase 4
Cooling Eyedrops for Dry Eye
Dry Eye
RecruitingPhase 2
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Sjögren's Syndrome
RecruitingObservational study
Characterization of Diseases With Salivary Gland Involvement
Healthy Volunteer, Sjogren's Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Penny Asbell, MD, MBA, FACS principal investigator
Icahn School of Medicine at Mount Sinai
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Systane Ultra, Saline solution and Maxidex in people with Dry Eye Disease, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
OSDI score (time frame: at Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2013.